Compare Nasdaq Inc (NDAQ) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Revvity Inc — how do they compare? Nasdaq Inc trades at $93.65 (market cap $51.63B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Nasdaq Inc is far larger — about 3× Revvity Inc's market cap, and Nasdaq Inc pays the higher dividend (1.26%). Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and Revvity Inc for 12 Days on average.
| NDAQ | RVTY | |
|---|---|---|
Market Cap | $51.63B | $16.98B |
Volume | 2,668,175 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $100.98 | $157.36 |
52-Week Low | $76.85 | $82.26 |
Typical Hold Time | 126 Days | 12 Days |
Enterprise Value | $58.09B | $19.30B |
Dividend Yield | 1.26% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $92.37, up 0.48% today, with a bullish technical signal from moving averages and strong fundamental performance including a 21.64% net income margin and consistent earnings beats. Recent news highlights growth in its Financial Technology business, such as HSBC adopting Nasdaq Calypso for derivatives clearing (GlobeNewsWire, 2026-09-28).
The outlook is positive with a consensus price target of $110.43, implying 19.6% upside, supported by robust profitability and AI-driven initiatives. Risks include high valuation multiples and market volatility, but analyst sentiment is strongly bullish with 61% buy ratings.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
